Histone deacetylases in control of skeletogenesis

Journal of Cellular Biochemistry

Volumn 102, Issue 2, 2007, Pages 332-340

  Westendorf, Jennifer J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chondrocyte; Epigenetics; Osteoblast; Osteoclast; Runx2

Indexed keywords

ANTICONVULSIVE AGENT; BUTYRIC ACID; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; SCOP 402; TRANSCRIPTION FACTOR RUNX2; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

AGING; BONE DEVELOPMENT; BONE REMODELING; BONE STRENGTH; CALCIUM TRANSPORT; CARTILAGE CELL; CELL MATURATION; CELL SURVIVAL; DRUG STRUCTURE; ENCHONDRAL OSSIFICATION; EPIGENETICS; GENE EXPRESSION REGULATION; HUMAN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW;

ANIMALS; BONE AND BONES; BONE DEVELOPMENT; BONE NEOPLASMS; BONE RESORPTION; CELL PROLIFERATION; CHONDROCYTES; GENE EXPRESSION REGULATION; HISTONE DEACETYLASES; HUMANS; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS;

VERTEBRATA;

EID: 34948880682     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21486     Document Type: Review

References (54)

1. Arnold MA, Kim Y, Czubryt MP, Phan D, McAnally J, Qi X, Shelton JM, Richardson JA, Bassel-Duby R, Olson EN. 2007. MEF2C transcription factor controls chondrocyte hypertrophy and bone development. Dev Cell 12:377-389.
2. Bernstein BE, Meissner A, Lander ES. 2007. The mammalian epigenome. Cell 128:669-681.
3. Boluk A, Guzelipek M, Savli H, Temel I, Ozisik HI, Kaygusuz A. 2004. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res 50: 93-97.
4. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN. 2004. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 24:8467-8476.
5. Chang S, Young BD, Li S, Qi X, Richardson JA, Olson EN. 2006. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 126: 321-334.
6. Chen TH, Chen WM, Hsu KH, Kuo CD, Hung SC. 2007. Sodium butyrate activates ERK to regulate differentiation of mesenchymal stem cells. Biochem Biophys Res Commun 355:913-918.
7. Cohen MM, Jr. 2006. The new bone biology: Pathologic, molecular, and clinical correlates. Am J Med Genet A 140:2646-2706.
8. de Boer JD, Licht R, Bongers M, Klundert TV, Arends R, Blitterswijk CV. 2006. Inhibition of Histone Acetylation as a Tool in Bone Tissue Engineering. Tissue Eng 12: 2927-2937.
9. Destaing O, Saltel F, Gilquin B, Chabadel A, Khochbin S, Ory S, Jurdic P. 2005. A novel Rho-mDia2-HDAC6 pathway controls podosome patterning through microtubule acetylation in osteoclasts. J Cell Sci 118:2901-2911.
10. Durst KL, Lutterbach B, Kummalue T, Friedman AD, Hiebert SW. 2003. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain. Mol Cell Biol 23:607-619.
11. Fan X, Roy EM, Murphy TC, Nanes MS, Kim S, Pike JW, Rubin J. 2004. Regulation of RANKL promoter activity is associated with histone remodeling in murine bone stromal cells. J Cell Biochem 93:807-818.
12. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP. 1999. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188-193.
13. Gregoretti IV, Lee YM, Goodson HV. 2004. Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. J Mol Biol 338: 17-31.
14. Guo CY, Ronen GM, Atkinson SA. 2001. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 42:1141-1147.
15. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. 2004. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64:1079-1086.
16. Hayashi M, Nimura K, Kashiwagi K, Harada T, Takaoka K, Kato H, Tamai K, Kaneda Y. 2007. Comparative roles of Twist-1 and Id1 in transcriptional regulation by BMP signaling. J Cell Sci 120:1350-1357.
17. Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF, Johanson K, Liu R, Lago A, Hofmann G, Macarron R, de los Frailes M, Perez P, Krawiec J, Winkler J, Jaye M. 2003. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 307:720-728.
18. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP. 2002. HDAC6 is a microtubule-associated deacetylase. Nature 417:455-458.
19. Iguchi H, Urashima Y, Inagaki Y, Ikeda Y, Okamura M, Tanaka T, Uchida A, Yamamoto TT, Kodama T, Sakai J. 2007. SOX6 suppresses cyclin D1 promoter activity by interacting with beta-catenin and histone deacetylase 1 and its down-regulation induces pancreatic beta-cell proliferation. J Biol Chem 282:19052-19061.
20. Iwami K, Moriyama T. 1993. Effects of short chain fatty acid, sodium butyrate, on osteoblastic cells and osteoclastic cells. Int J Biochem 25:1631-1635.
21. Jeon EJ, Lee KY, Choi NS, Lee MH, Kim HN, Jin YH, Ryoo HM, Choi JY, Yoshida M, Nishino N, Oh BC, Lee KS, Lee YH, Bae SC. 2006. Bone morphogenetic protein-2 stimulates Runx2 acetylation. J Biol Chem 281:16502-16511.
22. Jin YH, Jeon EJ, Li QL, Lee YH, Choi JK, Kim WJ, Lee KY, Bae SC. 2004. Transforming growth factor-beta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J Biol Chem 279:29409-29417.
23. Kang JS, Alliston T, Delston R, Derynck R. 2005. Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. Embo J 24:2543-2555.
24. Kim DW, Lassar AB. 2003. Smad-dependent recruitment of a histone deacetylase/Sin3A complex modulates the bone morphogenetic protein-dependent transcriptional repressor activity of Nkx3.2. Mol Cell Biol 23:8704-8717.
25. Kim K, Lee J, Kim JH, Jin HM, Zhou B, Lee SY, Kim N. 2007. Protein inhibitor of activated STAT 3 modulates osteoclastogenesis by down-regulation of NFATc1 and osteoclast-associated receptor. J Immunol 178:5588-5594.
26. Kitazawa R, Kitazawa S. 2007. Methylation status of a single CpG locus 3 bases upstream of TATA-box of receptor activator of nuclear factor-kappaB ligand (RANKL) gene promoter modulates cell- and tissue-specific RANKL expression and osteoclastogenesis. Mol Endocrinol 21:148-158.
27. Kouzarides T. 2007. Chromatin modifications and their function. Cell 128:693-705.
28. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, Schuettengruber B, Hauser C, Brunmeir R, Jenuwein T, Seiser C. 2002. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. Embo J 21:2672-2681.
29. Lee HW, Suh JH, Kim AY, Lee YS, Park SY, Kim JB. 2006a. Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation. Mol Endocrinol 20:2432-2443.
30. Lee JY, Lee YM, Kim MJ, Choi JY, Park EK, Kim SY, Lee SP, Yang JS, Kim DS. 2006b. Methylation of the mouse DIx5 and Osx gene promoters regulates cell type-specific gene expression. Mol Cells 22:182-188.
31. Lei Q, Jiao J, Xin L, Chang CJ, Wang S, Gao J, Gleave ME, Witte ON, Liu X, Wu H. 2006. N KX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 9:367-378.
32. Luo RX, Postigo AA, Dean DC. 1998. Rb interacts with histone deacetylase to repress transcription. Cell 92: 463-473.
33. Minucci S, Pelicci PG. 2006. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51.
34. Nakamura T, Kukita T, Shobuike T, Nagata K, Wu Z, Ogawa K, Hotokebuchi T, Kohashi O, Kukita A. 2005. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J Immunol 175:5809-5816.
35. Penolazzi L, Lambertini E, Giordano S, Sollazzo V, Traina G, del Senno L, Piva R. 2004. Methylation analysis of the promoter F of estrogen receptor alpha gene: Effects on the level of transcription on human osteoblastic cells. J Steroid Biochem Mol Biol 91:1-9.
36. Rahman MM, Kukita A, Kukita T, Shobuike T, Nakamura T, Kohashi O. 2003. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood 101:3451-3459.
37. Reid G, Metivier R, Lin CY, Denger S, Ibberson D, Ivacevic T, Brand H, Benes V, Liu ET, Gannon F. 2005. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene 24:4894-4907.
38. Sakata R, Minami S, Sowa Y, Yoshida M, Tamaki T. 2004. Trichostatin A activates the osteopontin gene promoter through AP1 site. Biochem Biophys Res Commun 315: 959-963.
39. Sato Y, Kondo I, Ishida S, Motooka H, Takayama K, Tomita Y, Maeda H, Satoh K. 2001. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 57:445-449.
40. Schroeder TM, Westendorf JJ. 2005. Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res 20:2254-2263.
41. Schroeder TM, Kahler RA, Li X, Westendorf JJ. 2004. Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem 279:41998-42007.
42. Smith E, Frenkel B. 2005. Glucocorticoids inhibit the transcriptional activity of LEF/TCF in differentiating osteoblasts in a glycogen synthase kinase-3beta-dependent and -independent manner. J Biol Chem 280:2388-2394.
43. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. 2006. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 281:5612-5622.
44. Vega RB, Matsuda K, Oh J, Barbosa AC, Yang X, Meadows E, McAnally J, Pomajzl C, Shelton JM, Richardson JA, Karsenty G, Olson EN. 2004. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119:555-566.
45. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, et al. 2001. The sequence of the human genome. Science 291:1304-1351.
46. Vestergaard P, Rejnmark L, Mosekilde L. 2004. Fracture risk associated with use of antiepileptic drugs. Epilepsia 45:1330-1337.
47. Villagra A, Gutierrez J, Paredes R, Sierra J, Puchi M, Imschenetzky M, Wijnen Av A, Lian J, Stein G, Stein J, Montecino M. 2002. Reduced CpG methylation is associated with transcriptional activation of the bone-specific rat osteocalcin gene in osteoblasts. J Cell Biochem 85: 112-122.
48. Wang Y, Belflower RM, Dong YF, Schwarz EM, O'Keefe RJ, Drissi H. 2005. Runx1/AML1/Cbfa2 mediates onset of mesenchymal cell differentiation toward chondrogenesis. J Bone Miner Res 20:1624-1636.
49. Westendorf JJ. 2006. Transcriptional co-repressors of Runx2. J Cell Biochem 98:54-64.
50. Westendorf JJ, Zaidi SK, Cascino JE, Kahler RA, van Wijnen AJ, Lian JB, Yoshida M, Stein G, Li X. 2002. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Biol Cell 22:7982-7992.
51. Yi T, Baek JH, Kim HJ, Choi MH, Seo SB, Ryoo HM, Kim GS, Woo KM. 2007. Trichostatin A-mediated upregulation of p21(WAF1) contributes to osteoclast apoptosis. Exp Mol Med 39:213-221.
52. Yoshida M, Matsuyama A, Komatsu Y, Nishino N. 2003. From discovery to the coming generation of histone deacetylase inhibitors. Curr Med Chem 10:2351-2358.
53. Yoshida CA, Yamamoto H, Fujita T, Furuichi T, Ito K, Inoue K, Yamana K, Zanma A, Takada K, Ito Y, Komori T. 2004. Runx2 and Runx3 are essential for chondrocyte maturation, and Runx2 regulates limb growth through induction of Indian hedgehog. Genes Dev 18:952-963.
54. Young DW, Hassan MQ, Yang XQ, Galindo M, Javed A, Zaidi SK, Furcinitti P, Lapointe D, Montecino M, Lian JB, Stein JL, van Wijnen AJ, Stein GS. 2007. Mitotic retention of gene expression patterns by the cell fate-determining transcription factor Runx2. Proc Natl Acad Sci U S A 104:3189-3194.